Resting-state functional dynamics alterations relate to plasma amyloid markers and statistically explain memory impairments in the TgF344-AD model of Alzheimer’s disease

Alzheimer’s Research & Therapy · Published 2026-07-17 · DOI 10.1186/s13195-026-02146-w

Free full text

Authors (8)

Alya Al-Awlaqi, Lori Berckmans, Sam De Waegenaere, Sarah Vanherle, Joseph Griffis, Ilse Dewachter, Marleen Verhoye, Mohit H. Adhikari

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Al-Awlaqi, A., Berckmans, L., Waegenaere, S., et al. (2026). Resting-state functional dynamics alterations relate to plasma amyloid markers and statistically explain memory impairments in the TgF344-AD model of Alzheimer’s disease. Alzheimer’s Research & Therapy. https://doi.org/10.1186/s13195-026-02146-w

Related articles

• Smoking cessation duration and risk of Alzheimer’s disease: a nationwide cohort study in Korea · Alzheimer’s Research & Therapy · 2026 · Same journal
• Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer’s disease: insights from the ADMET 2 trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Neural changes after computerized cognitive training in coronary heart disease with mild cognitive impairment: secondary analysis of a randomized clinical trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity · Alzheimer’s Research & Therapy · 2026 · Same journal
• Sequential associations of myelin dysfunction with Aβ and Tau pathology in Alzheimer's disease: a dynamic myelin perturbation · Alzheimer’s Research & Therapy · 2026 · Same journal
• Thresholds for meaningful change in Mini-Mental State Examination scores in rare dementias · Alzheimer’s Research & Therapy · 2026 · Same journal
• Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era · Alzheimer’s Research & Therapy · 2026 · Same journal
• Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer’s disease: randomised, controlled trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer’s disease: a systematic review and meta-analysis · Alzheimer’s Research & Therapy · 2026 · Same journal
• Development and validation of a harmonized memory score for multicenter Alzheimer’s disease and related dementia research · Alzheimer’s Research & Therapy · 2026 · Same journal